SCHEMBL315704

SCHEMBL315704

[CH2]Oc1ccc2ccccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 5/20 0.58
CYP1A2 P05177 3/20 0.58
AGXT P21549 2/20 0.52
TDP1 Q9NUW8 3/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPK1 P28482 1/20 0.50
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
ALOX5 P09917 1/20 0.48
GAA P10253 1/20 0.47
RCE1 Q9Y256 1/20 0.47
GPR84 Q9NQS5 1/20 0.47
PTPN7 P35236 1/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 1/20 0.44
CYP3A4 P08684 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2780134 0.92 CYP2A6 (0.50) CYP2A6CYP1A2AGXTTDP1KDM4E
SCHEMBL2779866 0.84 ALDH1A1 (0.54) CYP2A6CYP1A2AGXTTDP1GAA
SCHEMBL2781194 0.81 ALDH1A1 (0.56) CYP2A6CYP1A2AGXTTDP1MAPT
SCHEMBL3500443 0.80 CYP2A6 (0.67) CYP2A6CYP1A2AGXTTDP1KDM4E
SCHEMBL395026 0.78 CYP1A2 (0.64) CYP2A6CYP1A2AGXTTDP1KDM4E
SCHEMBL29366638 0.78 CYP1A2 (0.64) CYP2A6CYP1A2AGXTTDP1KDM4E
SCHEMBL29378143 0.76 CYP1A2 (0.61) CYP2A6CYP1A2AGXTTDP1KDM4E
Hydrochloric Acid SCHEMBL9443225 0.76 CYP1A2 (0.61) CYP2A6CYP1A2AGXTTDP1KDM4E
Ethylene SCHEMBL9815947 0.75 CYP1A2 (0.91) CYP2A6CYP1A2AGXTTDP1KDM4E
SCHEMBL27269655 0.75 CYP2A6 (0.52) CYP2A6CYP1A2TDP1KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 522 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1802303-B1 COMPOUNDS, COMPOSITIONS AND METHODS OF INHIBITING A-SYNUCLEIN TOXICITY WHITEHEAD BIOMEDICAL INST (US) 2011-11-02 EP claimed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US claimed
EP-1976839-A2 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING Foldrx Pharmaceuticals, Inc. (US) 2008-10-08 EP claimed
WO-2007089548-A2 COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2007-08-09 WO claimed
EP-1802303-A2 COMPOUNDS, COMPOSITIONS AND METHODS OF INHIBITING A-SYNUCLEIN TOXICITY WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2007-07-04 EP claimed
WO-2006034003-A2 COMPOUNDS, COMPOSITIONS AND METHODS OF INHIBITING A-SYNUCLEIN TOXICITY WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2006-03-30 WO claimed
EP-1074544-B1 Process for production of 3-(3-pyridyl)-1-propanol derivatives KANEKA CORP (JP) 2003-08-27 EP claimed
EP-1210598-A4 4-UNSUBSTITUTED DIHYDROISOQUINOLINONE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2002-10-30 EP claimed
US-6452009-B1 A LARGE NUMBER OF RELATED ANALOGS ARE THEN SYNTHESIZED IN ORDER TO DEVELOP A STRUCTURE-ACTIVITY RELATIONSHIP LION BIOSCIENCE AG (DE) 2002-09-17 US claimed
EP-1210598-A1 4-UNSUBSTITUTED DIHYDROISOQUINOLINONE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2002-06-05 EP claimed
US-6255120-B1 HYDROXYAMIDES ATTACHED TO SOLID SUPPORT PHARMACOPEIA, INC. 2001-07-03 US claimed
WO-2001014879-A1 4-UNSUBSTITUTED DIHYDROISOQUINOLINONE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-03-01 WO claimed
US-5976894-A FOR SCREENING BIOASSAYS TO DISCOVER BIOLOGICALLY ACTIVE MEMBERS PHARMACOPEIA, INC. (US) 1999-11-02 US claimed
EP-0667850-B1 TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS DOMPE FARMACEUTICI SPA (IT) 1997-05-28 EP claimed
US-5530128-A ENZYME INHIBITOR AS ANTITUMOR AGENT CELLTECH THERAPEUTICS LIMITED (GB) 1996-06-25 US claimed
EP-0667850-A1 TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS. DOMPE FARMACEUTICI SPA (IT) 1995-08-23 EP claimed
WO-1994010127-A1 TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS DOMPE' FARMACEUTICI S.P.A. (IT) 1994-05-11 WO claimed
US-5120849-A Reacting cyclic imidoether with aminoalcohol BASF AKTIENGESELLSCHAFT (DE) 1992-06-09 US claimed
EP-0127726-B1 HYDROXAMIC ACIDS, THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS VEB Fahlberg-List Magdeburg (DD) 1987-08-26 EP claimed
US-4112219-A Acyl derivatives of antibiotic BM123γ AMERICAN CYANAMID COMPANY (US) 1978-09-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT CYP2A6 3247/4885CYP1A2 2530/4885AGXT 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.